No proven upside to offset even mild risk: When benefit is uncertain, small and infrequent risks matter more Lipo-C should not displace interventions with strong outcome data (diet, activity, and, where indicated, approved pharmacotherapy)
Beyond gastrointestinal effects, clinical data and class-level evidence from licensed incretin agents (semaglutide, tirzepatide) have flagged concerns regarding: Heart rate elevation: Increases in resting heart rate are a recognised class effect of GLP-1 receptor agonists, documented in the SmPCs for semaglutide (Wegovy) and tirzepatide (Mounjaro)
Repeatedly using the same area can cause tissue damage, reduce absorption efficiency, and increase discomfort
Individual response to glutathione supplementation varies considerably
It sounds simple, but approvals for this code can be complicated